- Efficacy of probiotic bacteria Bacillus clausii in the treatment of acute gastroenteritis in children
Efficacy of probiotic bacteria Bacillus clausii in the treatment of acute gastroenteritis in children
Modern Pediatrics. Ukraine. (2026).2(154): 7-19. doi: 10.15574/SP.2026.2(154).719
Abaturov O. Ye.1, Kryuchko T. O.2, Nykulina A. O.1
1Dnipro State Medical University, Ukraine
2Poltava State Medical University, Ukraine
For citation: Abaturov OYe, Kryuchko TO, Nykulina AO. (2026). Efficacy of probiotic bacteria Bacillus clausii in the treatment of acute gastroenteritis in children. Modern Pediatrics. Ukraine. 2(154): 7-19. doi: 10.15574/SP.2026.2(154).719.
Article received: Feb 09, 2026. Accepted for publication: Mar 16, 2026.
Aim – to systematically review contemporary evidence on the efficacy of Bacillus clausii strains in the treatment of acute gastroenteritis (AGE) in children, assess the degree of inconsistency in the evidence base, and propose practical recommendations for pediatric clinical practice.
Narrative literature review with systematic search in PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar (2000-2026). PRISMA 2020 guidelines were followed. Fifty-four full-text articles (original studies, systematic reviews, and meta-analyses) containing data on Bacillus clausii use in children with acute gastroenteritis were included. No meta-analysis was performed due to data heterogeneity; qualitative synthesis was applied.
The mixture of Bacillus clausii strains (O/C, N/R, SIN, T) reduces the duration of diarrhea by an average of 9-14 hours, with a moderate standardized effect size, decreases stool frequency, and promotes faster clinical recovery in children with AGE, including rotavirus etiology. The effect is most pronounced during the first 3-5 days of treatment and in young children. Results of individual randomized trials are heterogeneous, ranging from statistically significant reduction of diarrhea duration by 12-34 hours to no significant difference compared to placebo. The preparation demonstrates a high safety profile and good tolerability without serious adverse events.
Conclusions. Bacillus clausii-based preparations may be recommended as adjunctive therapy in children with AGE, particularly within the first 24-48 hours of diarrhea onset, to shorten clinical manifestations and prevent severe dehydration. Further high-quality randomized trials are required to clarify strain-specific effects and definitively establish the role of Bacillus clausii in treatment algorithms.
The authors declare no conflict of interest.
Keywords: children, acute gastroenteritis, acute viral diarrhea, rotavirus infection, probiotic bacteria, Bacillus clausii, Bacillus clausii (O/C, N/R, SIN, T).
REFERENCES
1. Abaturov OE, Babych VL. (2016). Immunotropic effect of probiotic strains of Bacillus clausii. Pediatrics Eastern Europe. 4(4): 532-41.
2. Abbrescia A, Palese LL, Papa S, Gaballo A, Alifano P, Sardanelli AM. (2014, Dec). Antibiotic Sensitivity of Bacillus clausii Strains in Commercial Preparation. Curr Med Chem. 1(2): 102-110. Epub 2014 Dec. https://doi.org/10.2174/2212707002666150128195631; PMCid:PMC5388794
3. Acosta-Rodríguez-Bueno CP, Abreu Y Abreu AT, Guarner F, Guno MJV et al. (2022, Nov). Bacillus clausii for Gastrointestinal Disorders: A Narrative Literature Review. Adv Ther. 39(11): 4854-4874. Epub 2022 Aug 26. https://doi.org/10.1007/s12325-022-02285-0; PMid:36018495 PMCid:PMC9525334
4. Ahire JJ, Kashikar MS, Madempudi RS. (2020, Jun 10). Survival and Germination of Bacillus clausii UBBC07 Spores in in vitro Human Gastrointestinal Tract Simulation Model and Evaluation of Clausin Production. Front Microbiol. 11: 1010. https://doi.org/10.3389/fmicb.2020.01010; PMid:32733389 PMCid:PMC7358638
5. Bamola VD, Dubey D, Samanta P, Kedia S, Ahuja V, Madempudi RS et al. (2022, Dec). Role of a probiotic strain in the modulation of gut microbiota and cytokines in inflammatory bowel disease. Anaerobe. 78: 102652. https://doi.org/10.1016/j.anaerobe.2022.102652; PMid:36198385
6. Bhat S, Shreekrishna GN, Savio CD. (2018, Jun). Efficacy of probiotics in acute diarrhoea in children. Int J Contemp Pediatr. 5(4): 1646-1650. https://doi.org/10.18203/2349-3291.ijcp20182582
7. Bozdogan B, Galopin S, Gerbaud G, Courvalin P, Leclercq R. (2003, Apr). Chromosomal aadD2 encodes an aminoglycoside nucleotidyltransferase in Bacillus clausii. Antimicrob Agents Chemother. 47(4): 1343-1346. https://doi.org/10.1128/AAC.47.4.1343-1346.2003; PMid:12654668 PMCid:PMC152513
8. Bozdogan B, Galopin S, Leclercq R. (2004, Jan). Characterization of a new erm-related macrolide resistance gene present in probiotic strains of Bacillus clausii. Appl Environ Microbiol. 70(1): 280-4. https://doi.org/10.1128/AEM.70.1.280-284.2004; PMid:14711653 PMCid:PMC321311
9. Canani RB, Cirillo P, Terrin G, Cesarano L, Spagnuolo MI, De Vincenzo A et al. (2007). Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ. 335: 340. https://doi.org/10.1136/bmj.39272.581736.55; PMid:17690340 PMCid:PMC1949444
10. Chen C, Liu P, Xiao L, Cao Q, Zhou D, Liu X et al. (2026, Jan 12). Probiotics for treating acute diarrhea in children: an evidence synthesis. Front Pediatr. 13: 1722257. https://doi.org/10.3389/fped.2025.1722257; PMid:41602894 PMCid:PMC12832844
11. Cherif A, Rezgui W, Raddadi N, Daffonchio D, Boudabous A. (2008). Characterization and partial purification of entomocin 110, a newly identified bacteriocin from Bacillus thuringiensis subsp. Entomocidus HD110. Microbiol Res. 163(6): 684-692. https://doi.org/10.1016/j.micres.2006.10.005; PMid:19216106
12. Dang HT, Tran DM, Phung TTB, Bui ATP, Vu YH, Luong MT et al. (2024, Mar 18). Promising clinical and immunological efficacy of Bacillus clausii spore probiotics for supportive treatment of persistent diarrhea in children. Sci Rep. 14(1): 6422. https://doi.org/10.1038/s41598-024-56627-9; PMid:38494525 PMCid:PMC10944834
13. De Castro JA, Guno MJV, Perez MO. (2019, Jul 23). Bacillus clausii as adjunctive treatment for acute community-acquired diarrhea among Filipino children: a large-scale, multicenter, open-label study (CODDLE). Trop Dis Travel Med Vaccines. 5: 14. https://doi.org/10.1186/s40794-019-0089-5; PMid:31367461 PMCid:PMC6651909
14. De Castro JA, Kesavelu D, Lahiri KR, Chaijitraruch N, Chongsrisawat V, Jog PP et al. (2020, Oct 23). Recommendations for the adjuvant use of the poly-antibiotic-resistant probiotic Bacillus clausii (O/C, SIN, N/R, T) in acute, chronic, and antibiotic-associated diarrhea in children: consensus from Asian experts. Trop Dis Travel Med Vaccines. 6: 21. https://doi.org/10.1186/s40794-020-00120-4; PMid:33110611 PMCid:PMC7583175
15. Di Caro S, Tao H, Grillo A, Franceschi F, Elia C, Zocco MA et al. (2005, Sep). Bacillus clausii effect on gene expression pattern in small bowel mucosa using DNA microarray analysis. Eur J Gastroenterol Hepatol. 17(9): 951-960. https://doi.org/10.1097/00042737-200509000-00011; PMid:16093873
16. El-Fahla NA, El-Shenawy NS, Tawfik NM. (2026). Probiotic Bacillus Clausii Protects against Amoxicillin-evoked Reproductive Dysfunction through Oxidative Stress Modulation. Probiotics Antimicrob Proteins. Epub ahead of print. https://doi.org/10.1007/s12602-025-10891-x; PMid:41642431 PMCid:PMC13368905
17. Freedman SB, Finkelstein Y, Pang XL, Chui L, Tarr PI, VanBuren JM et al. (2022, Aug 24). Pathogen-Specific Effects of Probiotics in Children With Acute Gastroenteritis Seeking Emergency Care: A Randomized Trial. Clin Infect Dis. 75(1): 55-64. https://doi.org/10.1093/cid/ciab876; PMid:34596225 PMCid:PMC9402642
18. Fu L, Wang C, Ruan X, Li G, Zhao Y, Wang Y. (2018, Feb 2). Preservation of large yellow croaker (Pseudosciaena crocea) by Coagulin L1208, a novel bacteriocin produced by Bacillus coagulans L1208. Int J Food Microbiol. 266: 60-68. Epub 2017 Nov 21. https://doi.org/10.1016/j.ijfoodmicro.2017.11.012; PMid:29179097
19. Galopin S, Cattoir V, Leclercq R. (2009, Jun). A chromosomal chloramphenicol acetyltransferase determinant from a probiotic strain of Bacillus clausii. FEMS Microbiol Lett. 296(2): 185-189. Epub 2009 Apr 30. https://doi.org/10.1111/j.1574-6968.2009.01633.x; PMid:19459958
20. Ghelardi E, Abreu Y Abreu AT, Marzet CB, Álvarez Calatayud G et al. (2022, Jun 17). Current Progress and Future Perspectives on the Use of Bacillus clausii. Microorganisms. 10(6): 1246. https://doi.org/10.3390/microorganisms10061246; PMid:35744764 PMCid:PMC9230978
21. Guarino A, Aguilar J, Berkley J, Broekaert I, Vazquez-Frias R, Holtz L et al. (2020, May). Acute Gastroenteritis in Children of the World: What Needs to Be Done? J Pediatr Gastroenterol Nutr. 70(5): 694-701. https://doi.org/10.1097/MPG.0000000000002669; PMid:32079974 PMCid:PMC7613312
22. Hamid F, Quaium SMM, Rahman A. (2019, Apr). Comparative study of Bacillus clausii and multistrain probiotics in the management of acute diarrhoea in children. Int J Res Med Sci. 7(4): 1122-1127. https://doi.org/10.18203/2320-6012.ijrms20191317
23. Hartman S, Brown E, Loomis E, Russell HA. (2019, Feb 1). Gastroenteritis in Children. Am Fam Physician. 99(3): 159-165. Erratum in: Am Fam Physician. 2019 Jun 15; 99(12): 732. PMID: 30702253.
24. Ianiro G, Rizzatti G, Plomer M, Lopetuso L, Scaldaferri F, Franceschi F et al. (2018, Aug 12). Bacillus clausii for the Treatment of Acute Diarrhea in Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. 10(8): 1074. https://doi.org/10.3390/nu10081074; PMid:30103531 PMCid:PMC6116021
25. Khasawneh AI, Himsawi N, Sammour A, Bataineh FA, Odeh MH, Alhieh MS et al. (2025, Apr 30). Prevalence of Acute Gastroenteritis Enteropathogens Among Hospitalized Children in Jordan: A Single-Center Study. Viruses. 17(5): 657. https://doi.org/10.3390/v17050657; PMid:40431668 PMCid:PMC12116106
26. Kramarev SO, Zakordonets LV. (2019). Rotavirus infection: prevention and treatment. Child Health. 14; 3: 195-200. doi: 10.22141/2224-0551.14.3.2019.167389.
27. Lahiri KR, Jadhav K, Gahlowt P, Najmuddin F. (2015, May). Bacillus Clausii as an Adjuvant Therapy in Acute Childhood Diarrhoea. IOSR J Dent Med Sci. 14(5): 74-76. doi: 10.9790/0853-14517476.
28. Lahiri KR, Singh R, Apte M, Patil M, Taksande A, Varona R et al. (2022, Apr 10). Efficacy and safety of Bacillus clausii (O/C, N/R, SIN, T) probiotic combined with oral rehydration therapy (ORT) and zinc in acute diarrhea in children: a randomized, double-blind, placebo-controlled study in India. Trop Dis Travel Med Vaccines. 8(1): 9. https://doi.org/10.1186/s40794-022-00166-6; PMid:35397572 PMCid:PMC8994895
29. Maugo B, Jowi CY, Murila F, Laving A. (2021). Efficacy of Bacillus clausii in reducing duration of illness in acute diarrhoea in children 6-59 months of age admitted with severe dehydration. East Afr Med J. 98(5): 3649-3658.
30. Michel MC, Pellegrino P. (2025, Jul). A Comprehensive Review and Meta-analysis on the Treatment of Acute Gastroenteritis in Children with a Bacillus clausii Preparation (Enterogermina®). Adv Ther. 42(7): 3076-3088. Epub 2025 May 17. https://doi.org/10.1007/s12325-025-03221-8; PMid:40381158 PMCid:PMC12182463
31. Mouloud G, Daoud H, Bassem J, Laribi Atef I, Hani B. (2013, Dec). New bacteriocin from Bacillus clausii strainGM17: purification, characterization, and biological activity. Appl Biochem Biotechnol. 171(8): 2186-2200. Epub 2013 Sep 14. https://doi.org/10.1007/s12010-013-0489-3; PMid:24037515
32. Paparo L, Tripodi L, Bruno C, Pisapia L, Damiano C et al. (2020, Jul 28). Protective action of Bacillus clausii probiotic strains in an in vitro model of Rotavirus infection. Sci Rep. 10(1): 12636. https://doi.org/10.1038/s41598-020-69533-7; PMid:32724066 PMCid:PMC7387476
33. Pawłuszkiewicz K, Ryglowski PJ, Idzik N, Błaszczyszyn K, Kucharczyk E, Gaweł-Dąbrowska D et al. (2025, May 14). Rotavirus Infections: Pathophysiology, Symptoms, and Vaccination. Pathogens. 14(5): 480. https://doi.org/10.3390/pathogens14050480; PMid:40430800 PMCid:PMC12114175
34. Pradhan B, Guha D, Ray P, Das D, Aich P. (2016, Jun). Comparative Analysis of the Effects of Two Probiotic Bacterial Strains on Metabolism and Innate Immunity in the RAW 264.7 Murine Macrophage Cell Line. Probiotics Antimicrob Proteins. 8(2): 73-84. https://doi.org/10.1007/s12602-016-9211-4; PMid:27038159
35. Risøen PA, Rønning P, Hegna IK, Kolstø AB. (2004). Characterization of a broad range antimicrobial substance from Bacillus cereus. J Appl Microbiol. 96(4): 648-655. https://doi.org/10.1046/j.1365-2672.2003.02139.x; PMid:15012801
36. Rochín-Medina JJ, Ramírez-Medina HK, Rangel-Peraza JG, Pineda-Hidalgo KV, Iribe-Arellano P. (2018, Jan). Use of whey as a culture medium for Bacillus clausii for the production of protein hydrolysates with antimicrobial and antioxidant activity. Food Sci Technol Int. 24(1): 35-42. Epub 2017 Aug 17. https://doi.org/10.1177/1082013217724705; PMid:28816527
37. Sadrimovahed M, Ulusoy BH. (2024). Bacillus clausii: A Review into Story of Its Probiotic Success and Potential Food Applications. Fermentation. 10(10): 522. https://doi.org/10.3390/fermentation10100522
38. Salem MB, El-Lakkany NM, Hammam OA, Seif El-Din SH. (2024, Dec 16). Bacillus clausii spores maintain gut homeostasis in murine ulcerative colitis via modulating microbiota, apoptosis, and the TXNIP/NLRP3 inflammasome cascade. Toxicol Rep. 14: 101858. https://doi.org/10.1016/j.toxrep.2024.101858; PMid:39802600 PMCid:PMC11721221
39. Scaldaferri F, Graziani C, Mora V, Petito V, Lopetuso LR, Puca P et al. (2021). Bacillus clausii (O/C, SIN, N/R, T) improves acute mild colitis in mice while in-vivo modulating gut microbiota. Ann Gastroenterol Dig Syst. 4(1): 1035.
40. Schmidt MA, Groom HC, Rawlings AM, Mattison CP, Salas SB, Burke RM et al. (2022, Nov). Incidence, Etiology, and Healthcare Utilization for Acute Gastroenteritis in the Community, United States. Emerg Infect Dis. 28(11): 2234-2242. https://doi.org/10.3201/eid2811.220247; PMid:36285882 PMCid:PMC9622243
41. Schnadower D, O'Connell KJ, VanBuren JM, Vance C, Tarr PI, Schuh S et al. (2021, Jul 1). Association Between Diarrhea Duration and Severity and Probiotic Efficacy in Children With Acute Gastroenteritis. Am J Gastroenterol. 116(7): 1523-1532. https://doi.org/10.14309/ajg.0000000000001295; PMid:34183579 PMCid:PMC8259780
42. Schnadower D, Tarr PI, Casper TC, Gorelick MH, Dean JM, O'Connell KJ et al. (2018, Nov 22). Lactobacillus rhamnosus GG versus Placebo for Acute Gastroenteritis in Children. N Engl J Med. 379(21): 2002-2014. https://doi.org/10.1056/NEJMoa1802598; PMid:30462938 PMCid:PMC6358014
43. Shaikh SS, Patel SS, Verma S, Malik A, Malek F. (2025, Aug 7). Safety Assessment and Efficacy of Probiotic Bacillus clausii PBC429™ (MTCC 25459) for Management of Diarrhea. Probiotics Antimicrob Proteins. Epub ahead of print. https://doi.org/10.1007/s12602-025-10670-8; PMid:40773042
44. Smiyan OI, Smiian-Horbunova KO, Bynda TP, Loboda AM, Popov SV, Vysotsky IY et al. (2019). Optimization of the treatment of rotavirus infection in children by using bacillus clausii. Wiad Lek. 72(7): 1320-1323. https://doi.org/10.36740/WLek201907117; PMid:31398163
45. Soloviov SO, Todosiichuk TS, Kovaliuk OV, Filippelli GM, Trokhymenko OP et al. (2022, Apr 12). Rotaviruses and Noroviruses as Etiological Agents of Acute Intestinal Diseases of Ukrainian Children. Int J Environ Res Public Health. 19(8): 4660. https://doi.org/10.3390/ijerph19084660; PMid:35457527 PMCid:PMC9030432
46. Söylemez-Milli N, Ertürkmen P, Alp Baltakesmez D. (2025, Feb 5). The Resistance Abilities of Some Bacillus Species to Gastrointestinal Tract Conditions: Whole Genome Sequencing of the Novel Candidate Probiotic Strains Bacillus clausiiBA8 and Bacillus subtilisBA11. Food Sci Nutr. 13(2): e70018. https://doi.org/10.1002/fsn3.70018; PMid:39911839 PMCid:PMC11795423
47. Stanyevic B, Sepich M, Biondi S, Baroncelli GI, Peroni D, Di Cicco M. (2022, Jan). The evolving epidemiology of acute gastroenteritis in hospitalized children in Italy. Eur J Pediatr. 181(1): 349-358. Epub 2021 Jul 29. https://doi.org/10.1007/s00431-021-04210-z; PMid:34327610 PMCid:PMC8760218
48. Subramanian S, Mitkus E, Souleimanov A, Smith DL. (2023, Aug 4). Lipo-chitooligosaccharide and thuricin 17 act as plant growth promoters and alleviate drought stress in Arabidopsis thaliana. Front Microbiol. 14: 1184158. https://doi.org/10.3389/fmicb.2023.1184158; PMid:37601342 PMCid:PMC10436337
49. Subramanian S, Smith DL. (2015, Oct 30). Bacteriocins from the rhizosphere microbiome – from an agriculture perspective. Front Plant Sci. 6: 909. PMID: 26579159; PMCID: PMC4626563. https://doi.org/10.3389/fpls.2015.00909
50. Sudha MR, Jayanthi N, Pandey DC, Verma AK. (2019, Mar 13). Bacillus clausii UBBC-07 reduces severity of diarrhoea in children under 5 years of age: a double blind placebo controlled study. Benef Microbes. 10(2): 149-154. Epub 2019 Jan 14. https://doi.org/10.3920/BM2018.0094; PMid:30638396
51. Szajewska H, Berni Canani R, Domellöf M, Guarino A, Hojsak I, Indrio F et al. (2023, Feb 1). Probiotics for the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications. J Pediatr Gastroenterol Nutr. 76(2): 232-247. Epub 2022 Oct 11. https://doi.org/10.1097/MPG.0000000000003633; PMid:36219218
52. Tkakiev MY, Krivochko MY, Chernusova SN, Mikhailenko EP. (2013). Safe and effective enteroprotective therapy of rotavirus infection in children. Sovrem Pediatriya. (7): 109-112.
53. Tóth AG, Csabai I, Judge MF, Maróti G, Becsei Á et al. (2021, Oct 21). Mobile Antimicrobial Resistance Genes in Probiotics. Antibiotics (Basel). 10(11): 1287. https://doi.org/10.3390/antibiotics10111287; PMid:34827225 PMCid:PMC8614787
54. Wong-Chew RM, de Castro JA, Morelli L, Perez M, Ozen M. (2022, Jul). Gut immune homeostasis: the immunomodulatory role of Bacillus clausii, from basic to clinical evidence. Expert Rev Clin Immunol. 18(7): 717-729. Epub 2022 Jun 19. https://doi.org/10.1080/1744666X.2022.2085559; PMid:35674642
55. Xie H, Yu T, Zhou Q, Na K, Lu S et al. (2025, Dec). Comparative Evaluation of Spores and Vegetative Forms of Bacillus subtilis and Bacillus licheniformis on Probiotic Functionality In Vitro and In Vivo. Probiotics Antimicrob Proteins. 17(6): 4709-4727. Epub 2024 Nov 28. https://doi.org/10.1007/s12602-024-10407-z; PMid:39607632